MANP in Hypertension With Metabolic Syndrome

Figures

• 

  Figure 1. Structure and Amino Acid Sequence of MANP Amino acid sequence in red highlights the unique C-terminal extension of M-atrial natriuretic peptide (MANP) compared to native ANP.

• 

  Figure 2. Consort Flow Diagram of the Study Design A schematic summary of the study protocol. BMI = body mass index; MANP = M-atrial natriuretic peptide.

• 

  Figure 3. Effects of Subcutaneous Injection of MANP on Plasma ANP-Like Peptides and cGMP Changes in circulating levels of atrial natriuretic peptide (ANP)-like peptides (M-atrial natriuretic peptide [MANP] and endogenous ANP) (A) and 3′, 5′–cyclic guanylyl monophosphate (cGMP) (B) during 24-hour post subcutaneous administration of MANP or placebo. Shown P values represent the comparison to baseline. ∗P < 0.05. &P = 0.059 at 1-hour post MANP administration. Data are mean ± SEM. Data compared using repeated measures analysis of variance with Scheffe post hoc test.

• 

  Figure 4. Effects of Subcutaneous Injection of MANP on Sitting BP Changes in sitting systolic blood pressure (BP) (A), sitting diastolic BP (B), and heart rate (C) during 24-hour post subcutaneous administration of M-atrial natriuretic peptide (MANP) or placebo. $P < 0.10 compared to baseline; #P < 0.07 compared to placebo group. Data are mean ± SEM. Data compared using repeated measures analysis of variance with Scheffe post hoc test.

• 

  Figure 5. Correlations Between Baseline Features and MANP Response in BP Reduction Spearman correlation analysis on baseline characteristics and response to MANP. The responses to MANP are represented by the mean systolic BP change (A) and the mean diastolic BP change (B). For each subject, mean BP (systolic or diastolic) change is defined as the mean value of BP change among 0.5, 1, 2, 4, 6, 12, and 24 hours post MANP administration. (A, B) Each circle represents 1 subject with blue indicating male gender and red indicating female gender. ∗P < 0.05. Abbreviations as in Figures 1, 2, 3, and 4.